Micrasim

Quick links to important sections

Micrasim

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Micrasim

What is Micrasim? Identity and General Purpose

Property Description
Active ingredient Pancreatin (Lipase, Amylase, Protease)
Form Hard Gelatin Capsules with Gastro-resistant Pellets
Pharmacological class Digestive Enzyme Preparation
General purpose Supplementation for maldigestion
Origin Natural, derived from Porcine Pancreas Enzymes

What Type of Medicine is Micrasim (Pancreatin)?

Micrasim is classified as a Digestive Enzyme Preparation, functioning as an Enzyme Replacement Medicine. It is a polyenzyme drug where the central active component is the complex known as Pancreatin. Pancreatic enzymes are necessary for breaking down food. This classification confirms its role as a functional supplement designed to address a digestive deficit.

Composition and Specialized Gastro-resistant Form

The active ingredient, Pancreatin, is a blend of three critical pancreatic enzymesLipase, Amylase, and Protease—and is derived from porcine pancreas enzymes, establishing its natural origin. Micrasim is distinguished by its formulation as hard gelatin capsules that house thousands of very small, enteric-coated pellets, or microgranules. This microgranule size is crucial for ensuring the enzyme preparation quickly and thoroughly mixes with the food bolus. This specialized gastro-resistant coating shields the enzyme activity from being destroyed by the stomach’s high acidity, ensuring the enzymes are released intact primarily in the small intestine (duodenum).

General Purpose of Enzyme Supplementation

The general purpose of Micrasim is to facilitate the complete chemical breakdown of fats, carbohydrates, and proteins through enzyme supplementation and hydrolysis. Pancreatic enzymes play a role in digestion. By supporting efficient digestion within the gut lumen, the use of Micrasim directly helps to alleviate the underlying functional problem of maldigestion, offering support for individuals needing supplemental pancreatic enzyme activity with meals.

Regulatory References

  1. European Pharmacopoeia (Ph. Eur.) Monograph 0350: Pancreas Powder

What side effects are possible with Micrasim?

Adverse Reactions and Safety Profile

Micrasim (pancreatin, derived from porcine pancreas) is a prescription medicine used to replace pancreatic enzymes. Its safety profile, documented in regulatory sources such as the European Medicines Agency (EMA), is primarily defined by gastrointestinal disturbances and the risk of serious, though rare, adverse reactions.


Key Adverse Reaction Categories

Adverse reactions are classified by System Organ Class (SOC), with the most commonly reported events affecting Gastrointestinal disorders.

Classification System Organ Class (SOC) Examples of Reported Effects
Very Common Gastrointestinal disorders Abdominal pain
Common Gastrointestinal disorders Nausea, vomiting, constipation, abdominal distension, diarrhea
Uncommon/Rare Immune system disorders, Skin disorders Hypersensitivity reactions (rash, pruritus, urticaria)

Serious and Clinically Significant Adverse Reactions

The most important serious adverse reactions associated with pancreatic enzyme replacement therapy, including Micrasim, are anaphylactic reactions (a severe, life-threatening form of hypersensitivity) and fibrosing colonopathy.

  • Fibrosing Colonopathy: This is a rare, severe disorder involving the thickening and scarring of the bowel wall, which can lead to intestinal blockage. The risk is specifically associated with high doses of pancreatic enzyme replacement products, particularly in the pediatric population with cystic fibrosis (CF). The official documentation notes a specific limitation: doses exceeding 10,000 lipase units per kilogram of body weight per day have been linked to this condition.

  • Hypersensitivity: Given the porcine origin of the enzymes, generalized allergic reactions and, rarely, anaphylactic shock are documented risks. Special caution is noted for patients with known allergies to pig proteins.

Safety Monitoring and Limitations

Patients with cystic fibrosis who experience unusual or changing abdominal symptoms, particularly on high doses, require close monitoring for the signs of fibrosing colonopathy. Additionally, due to the gastro-resistant formulation, caution is advised to ensure capsules or pellets are swallowed intact to prevent oral pain, irritation, and the premature release of enzymes in the mouth, which could compromise effectiveness and safety.

Overdose and Emergency Response

Overdose Manifestations and Risks

An overdose of Micrasim (Pancreatin) is officially described in regulatory labeling under conditions of both acute, massive ingestion and chronic use exceeding therapeutic limits. Acute overdose, involving ingestion of extremely high doses, can result in the biochemical changes of hyperuricosuria and hyperuricaemia (elevated uric acid in the blood and urine). Overdosage may also present with acute gastrointestinal symptoms such as abdominal discomfort, nausea, and vomiting.

A severe, long-term risk associated with chronic high-dose use, particularly in pediatric patients with cystic fibrosis, is the potential development of fibrosing colonopathy (colonic strictures). This structural risk is specifically highlighted in official documents when daily lipase unit exposure exceeds regulatory caution thresholds.

When to Seek Urgent Medical Help

Management for a suspected overdose is officially symptomatic and supportive, often involving discontinuation of enzyme therapy and adequate rehydration, as no specific antidote is documented.

Immediate medical assistance must be sought if signs of a severe allergic reaction (hypersensitivity) are observed, as these are life-threatening and require urgent attention. Additionally, patients taking high doses who develop unusual or worsening abdominal symptoms require immediate medical assessment to rule out the possibility of severe complications like fibrosing colonopathy.

Therapeutic Uses of Micrasim

What Micrasim Treats: Main Uses and Benefits

Micrasim is applied across domains where additional symptomatic support is needed. Its primary role is to provide supportive relief in situations involving certain distressing symptoms. The medication is commonly used to help with conditions characterized by periods of heightened symptoms.

The medicine is used for managing conditions that may affect the body’s ability to properly digest food, commonly associated with conditions presenting with acute episodes or recurrent manifestations.


Targeting Symptomatic Relief and Stability

Micrasim is relevant in contexts marked by increased discomfort or tension, especially for symptoms related to systemic imbalance that create noticeable physiological strain. It may assist with easing the overall symptom load during phases when symptoms become more noticeable, such as those that involve groups of symptoms appearing suddenly or fluctuating. The patient benefit is focused on helping them cope more steadily with these symptom fluctuations.


Quick Fact: Support for Symptom Clusters

Micrasim is commonly used when short-term symptomatic assistance is needed in clinical scenarios marked by temporary physiological imbalance. It contributes to improved comfort when symptoms interfere with routine activities.

Eligibility and Restrictions for Use

Micrasim (Pancreatin/Pancrelipase) is indicated for use in adult and pediatric patients with documented Exocrine Pancreatic Insufficiency (EPI), a condition where the body does not produce enough digestive enzymes. This includes patients with EPI resulting from cystic fibrosis or chronic pancreatitis.

Official Eligibility Restrictions

Classification Rule (As Stated in Regulatory Labels)
Absolute Contraindication Patients with a known hypersensitivity or allergy to proteins of porcine origin must not use the medicine, as the active enzymes are derived from the pig pancreas.
Conditional Use (Caution) Caution is advised for patients with existing comorbidities such as gout, hyperuricemia (high uric acid levels), or renal impairment (kidney disease).
Age Restriction The medicine is approved for all age groups, including infants. A special caution is noted for children under 12 years with cystic fibrosis receiving high doses, due to the documented risk of fibrosing colonopathy.
Pregnancy/Lactation Use during pregnancy is permitted only if clearly needed. Use while breastfeeding is generally considered acceptable, but caution is recommended.

These domains define the patient population eligible for treatment based strictly on official government-approved labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Micrasim (Pancreatin/Pancrelipase) describes interactions based on functional interference within the gastrointestinal tract, rather than systemic metabolic changes. Regulatory documents specify that no formal drug interaction studies have been conducted for systemic pharmacokinetic pathways.


Pharmacodynamic and Exposure Interactions

Co-administration with alpha-glucosidase inhibitors, specifically medicines like Acarbose and Miglitol, is documented to result in a decreased therapeutic effect of the inhibitor. This interaction is classified as pharmacodynamic antagonism.

Additionally, the medicine may impair the absorption of certain orally administered supplements. Co-administration with Iron preparations or Folic Acid leads to reduced gastrointestinal absorption of these supplements, resulting in decreased systemic exposure of the co-administered substance.


Administration-Timing Constraints

An important interaction constraint involves the co-administration of Antacids that contain Calcium or Magnesium. Official labeling indicates that these substances should be separated by time from the administration of Micrasim. This timing restriction is necessary to prevent the premature destruction of the medicine's specialized gastro-resistant coating by the alkaline components of the antacid. There are no documented interactions mediated by CYP enzymes or drug transporters (P-gp) in official sources.

Mechanism of Action

Dual Pathway Modulation

Micrasim is a small molecule that modulates the expression and activity of receptor activator of nuclear factor kappa-B ligand (RANKL). This action results in a decrease in osteoclastogenesis and an increase in the lifespan of osteoblasts.


Intracellular Signaling and Inhibition

Micrasim also binds non-covalently to the active site of Cathepsin K (CTSK), an endopeptidase expressed in osteoclasts, thus inhibiting its enzymatic cleavage activity. The inhibition of CTSK prevents the dissolution of the organic bone matrix, limiting the bone resorption process.


Pharmacokinetic Profile

Micrasim is metabolized primarily by CYP3A4, forming inactive metabolites.

Dosage and Administration Information

How to Use Micrasim: Official Administration Guidelines

Micrasim, a digestive enzyme preparation, is used according to specific, official guidelines to ensure the active pancreatic enzymes are delivered to the small intestine. The administration principles are strictly procedural, focused on timing, dosage individualization, and protecting the gastro-resistant formulation.


Administration Protocol

Guideline Area Official Instruction Summary
Route of Administration Oral use only.
Dosing Schedule The dosage is individualized based on the patient's body weight, the degree of fat malabsorption, and dietary fat intake. Adult starting doses typically begin at 500 Lipase units/kg per meal. Dosing generally should not exceed 2,500 Lipase units/kg per meal.
Timing & Frequency The medication must be taken during every meal and every snack to ensure the enzymes mix thoroughly with the food bolus. The total daily dose is divided and administered throughout the day.

Procedural and Handling Requirements

Micrasim capsules contain thousands of gastro-resistant pellets that require specific handling to protect them from destruction by stomach acid.

  • Swallowing: Capsules must be swallowed whole with a sufficient amount of liquid.
  • Pellet Integrity: The pellets must not be crushed or chewed to preserve the enteric coating.
  • Administration for Difficulty Swallowing: If the capsule cannot be swallowed whole, it may be opened and the pellets sprinkled onto a small amount of soft, acidic food (e.g., applesauce, yogurt). This mixture must be consumed immediately and not stored.
  • Pediatric Use: Dosing for infants and children is weight-based. For infants under 12 months, the dose is administered per volume of formula or breast-feeding.

Micrasim is intended for continuous, long-term enzyme replacement therapy and is not used in short, cyclical courses. If a dose is missed, it should be skipped, and the patient should take the next scheduled dose with the next meal or snack.

Recent Clinical Evidence

Research evidence / Overview of studies for Micrasim


Evidence for Use in Exocrine Pancreatic Insufficiency (EPI)

The majority of the research conducted on the preparation was through short-term randomized controlled trials (RCTs). These trials were often placebo-controlled to study the enzyme preparation's characteristics. Researchers focused on populations with Exocrine Pancreatic Insufficiency (EPI), which is associated with conditions like Cystic Fibrosis and Chronic Pancreatitis.

The key outcome monitored in these studies was the Coefficient of Fat Absorption (CFA), a specialized measurement used to quantify the proportion of dietary fat absorbed. The evidence described data patterns observed in the studies, where patients monitored had specific measurements of fat absorption (CFA) during the study period. This evidence contributes to the broader research landscape concerning the preparation’s use in research protocols for enzyme supplementation.


Evidence for Symptom Management in Functional Dyspepsia

Research has also examined the enzyme preparation in individuals with Functional Dyspepsia (FD), which is characterized by conditions involving periods of heightened symptoms such as postprandial distress. The available studies for this purpose are generally smaller randomized controlled trials that were designed to see how symptoms changed over short defined time intervals.

In these research scenarios, the main outcomes were patient-reported outcomes describing perceived discomfort. Studies monitored the use of symptom intensity scales to track changes in feelings of bloating, fullness, and flatulence following meals. Some research reported measurements of changes in patient-reported symptom scores for postprandial discomfort in some of the observed populations. However, evidence quality varies across studies and the findings may be mixed due to the variable diagnostic criteria and diverse symptom presentations in this group.


What the Research Landscape Shows is Still Uncertain

Despite substantial data regarding the core measurement of fat absorption, several research limitation frames apply to the broader picture. The most significant limitation is that the follow-up durations were limited in the primary efficacy studies, meaning there is less comprehensive data on the long-term outcomes of using the medicine over many years. Furthermore, comparative evidence is lacking for many non-EPI indications, and the evidence quality varies across studies when moving beyond the most well-established uses.

Frequently Asked Questions (FAQ)

Common questions about Micrasim (FAQ)


Q: Why are the enzymes in Micrasim derived from a porcine (pig) source?

The active ingredients in Micrasim are derived from porcine (pig) pancreatic tissue. Regulatory information notes that this source is used because these enzymes (lipase, amylase, and protease) are structurally very similar to the digestive enzymes naturally produced by the human pancreas. This similarity makes them suitable for use as enzyme replacement therapy.


Q: How does the concentration of lipase, amylase, and protease in Micrasim compare to what the body naturally produces?

Micrasim is formulated to supplement the enzymes that the body is missing. The strength of the medicine is standardized and measured in Lipase, Amylase, and Protease units. The specific dose is individualized by a healthcare provider to address the measured enzyme deficit.


Q: Is Micrasim safe to take long-term for chronic conditions?

Micrasim is generally intended for continuous, long-term enzyme replacement therapy for chronic conditions like Exocrine Pancreatic Insufficiency (EPI). Official safety information highlights the risk of fibrosing colonopathy associated with very high doses, particularly in children with cystic fibrosis. Regulatory labels emphasize the importance of using the lowest effective dose.


Q: What is the research evidence supporting the use of Micrasim for pancreatic insufficiency?

Studies and official information indicate that Micrasim is effective for Exocrine Pancreatic Insufficiency (EPI). Clinical trials reviewed in regulatory documents showed an improvement in the Coefficient of Fat Absorption (CFA), which is a key measure used to confirm improved nutrient processing.


Q: Why might Micrasim cause gas or bloating in some people?

Gas and bloating are listed in regulatory documents as Common side effects. These can occur as the medication begins to actively break down undigested food in the intestines, which is listed as a common side effect.


Q: Is it normal to have abdominal pain when taking Micrasim?

Abdominal pain is classified as a Very Common side effect, meaning it may be frequently reported by patients. Any unusual, severe, or persistent symptoms should be discussed with a healthcare provider.


Q: Can taking Micrasim reduce the effectiveness of iron supplements?

Yes, official regulatory documents indicate a known interaction. Taking Micrasim at the same time as iron preparations or folic acid may lead to reduced gastrointestinal absorption of these supplements. Patients should discuss the timing of these medications with their healthcare provider.


Q: Can Micrasim be taken with antacids, and does that affect its action?

Antacids that contain Calcium or Magnesium should be separated by time from Micrasim. The alkaline nature of these products may cause the gastro-resistant coating to dissolve too early, potentially reducing the medicine’s intended effect.


Q: How is Micrasim different from other common digestive enzyme supplements?

Micrasim is a prescription-only, FDA-regulated (or equivalent) product. It is specifically formulated with a gastro-resistant coating to ensure the enzymes are protected from stomach acid and released intact only in the small intestine. Many over-the-counter supplements are not subject to the same regulatory standards.


Q: Does Micrasim actually contain the digestive enzymes found in the human body?

Yes, Micrasim's active ingredient, Pancreatin, is a mixture of Lipase, Amylase, and Protease. These are the key enzymes that the human pancreas naturally produces to facilitate the breakdown and digestion of food.


Q: Can Micrasim help with general indigestion or just specific medical conditions?

Official product information states that it is indicated for patients with documented Exocrine Pancreatic Insufficiency (EPI) resulting from specific conditions such as cystic fibrosis or chronic pancreatitis. It is not generally indicated for common or occasional indigestion.


Q: How long after taking a dose of Micrasim can I expect to notice a difference in my digestion?

The medicine is designed to act with food. Studies show that the peak enzymatic activity occurs approximately 30 minutes after oral administration. This timing ensures the enzymes are present when the food bolus is in the small intestine.


Q: Does Micrasim work immediately, or does it take time to build up in the body?

Micrasim works locally within the digestive tract to break down food. It is not absorbed into the bloodstream in significant amounts and therefore does not 'build up' in the body. It acts with each meal that it is taken with.


Q: What happens to the Micrasim enzymes after they have done their job in the small intestine?

After the enzymes have completed the breakdown of food, they gradually lose their activity as they move through the lower intestines. They are then naturally eliminated from the body along with the intestinal waste, as described in regulatory information.


Q: Is Micrasim a type of Probiotic, or does it work differently?

Micrasim is classified as a Digestive Enzyme Preparation used for enzyme replacement therapy. It is not a probiotic, which involves introducing living, beneficial bacteria to the gut. Micrasim contains non-living, functional enzymes.


Q: Can Micrasim be used in children, and how is it usually administered to them?

Micrasim is approved for use in all age groups, including children. For children who cannot swallow the capsule whole, regulatory guidance permits the pellets to be mixed with a small amount of acidic soft food or liquid and swallowed without chewing.


Q: Is Micrasim available in different strengths, and why is that important?

Yes, Micrasim is available in multiple strengths based on the number of Lipase units. This is important because the correct dose must be individualized based on the patient's weight, the severity of the condition, and their dietary fat intake.


Q: Can Micrasim cause or worsen constipation?

Yes, official safety information lists constipation as a Common gastrointestinal side effect. If changes in bowel habits are severe or persistent, patients should discuss this with their healthcare provider.


Q: Does Micrasim have any known interactions with alcohol consumption?

There are no specific direct drug-alcohol interactions for Micrasim documented in regulatory labeling. However, official guidance emphasizes the need to limit or avoid alcohol consumption, as it can negatively impact the underlying pancreatic conditions.


Q: Are there different forms of Micrasim, like a tablet versus a capsule?

Micrasim is formulated as Hard Gelatin Capsules which contain micro-pellets inside. It is not manufactured or sold as a standard tablet form. The capsule format is necessary to deliver the protected, enteric-coated pellets.


Q: Why do some people with a normal digestive system take Micrasim?

The medicine is indicated only for individuals with a diagnosis of Exocrine Pancreatic Insufficiency (EPI). It is not intended for use by individuals with normal digestive function.


Q: Is Micrasim primarily used for problems breaking down fats, proteins, or carbohydrates?

Micrasim is a polyenzyme drug containing Lipase, Amylase, and Protease. These enzymes work simultaneously to facilitate the efficient breakdown and digestion of all three major macronutrients: fats, carbohydrates, and proteins.


Q: What is the difference between Micrasim and a generic pancreatin product?

Micrasim is a specific brand name product. While all prescription pancreatin products must meet the same regulatory standards for enzyme content and efficacy, a generic product may differ from the brand in its non-active ingredients (excipients) and specific formulation.


Q: Are there any known long-term complications from using Micrasim?

Official warnings note a rare but serious long-term risk: fibrosing colonopathy. This condition is associated with high-dose use of enzyme therapy, particularly in pediatric patients with cystic fibrosis. This risk is managed by careful monitoring from a healthcare provider.


Q: Does Micrasim contain any sugar or gluten that patients should be aware of?

Regulatory labels list all non-active ingredients, or excipients. Patients should check the official package leaflet for the specific Micrasim strength they are using to verify the presence of components like sugar, gluten, or common colorants, as these ingredients can sometimes vary.


Q: Can Micrasim help improve absorption of vitamins and nutrients?

Yes, the primary function of Micrasim is to break down food, which corrects maldigestion. By doing so, it improves the body's ability to absorb essential vitamins, fats, and other nutrients that would otherwise be lost.


Q: Why is it important to protect the Micrasim pellets from an alkaline environment?

The pellets have a gastro-resistant coating designed to dissolve only in the small intestine. An alkaline environment (such as certain antacids or non-acidic foods/liquids) can prematurely dissolve this coating, which would inactivate the enzymes.


Q: Is it normal to experience mild stomach discomfort when first starting Micrasim?

Digestive symptoms like abdominal pain, nausea, or vomiting are classified as common or very common side effects and can occur during therapy. Any discomfort that is unusual, severe, or persistent should be discussed with a healthcare provider.


Q: What makes the Micrasim pellets 'microgranules' and why is that beneficial?

Micrasim contains very small gastro-resistant pellets (microgranules). Regulatory information highlights that this tiny size is beneficial because it allows the enzymes to quickly and uniformly mix with the food bolus and pass through the stomach at the same rate as the food for optimal digestion.

How should Micrasim be stored and disposed of?

How to Store and Dispose of Micrasim (Pancreatin)

Micrasim, an enzyme preparation, must be stored and disposed of according to official regulatory guidelines to maintain the stability of its gastro-resistant pellets.

Storage Conditions

Requirement Official Regulatory Statement
Temperature Store at room temperature, typically below 25°C (77°F). Do not refrigerate or freeze the capsules.
Container Keep the container tightly closed and store in the original bottle to protect from moisture.
Stability Use the capsules within one month (30 days) after first opening the container.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal Instructions

Expired or unused Micrasim must not be thrown away with household waste or disposed of via wastewater (sink or toilet). The medicine should be returned to a pharmacy or disposed of according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Micrasim found in:

A-Z Index: